Document is current
Any future updates will be listed below
-
Authors
Dimitriou, Florentia https://orcid.org/0000-0003-4529-3372
Cheng, Phil F. https://orcid.org/0000-0003-2940-006X
Saltari, Annalisa
Schaper-Gerhardt, Katrin
Staeger, Ramon https://orcid.org/0000-0002-9283-9596
Haunerdinger, Veronika
Sella, Federica https://orcid.org/0000-0002-0805-0905
Tastanova, Aizhan https://orcid.org/0000-0003-1120-5610
Urban, Christian
Dettwiler, Susanne
Mihic-Probst, Daniela
Matter, Christian M.
Michielin, Olivier
Gutzmer, Ralf https://orcid.org/0000-0001-7921-2820
Long, Georgina V. https://orcid.org/0000-0001-8894-3545
Becher, Burkhard https://orcid.org/0000-0002-1541-7867
Levesque, Mitchell P. https://orcid.org/0000-0001-5902-9420
Dummer, Reinhard https://orcid.org/0000-0002-2279-6906
-
Funding
Funding for this research was provided by:
Schweizerische Akademie der Medizinischen Wissenschaften (YTCR 01/22)
Iten-Kohaut Stiftung and the USZ Foundation
- License Information
-
More Information
Article History
Received: 1 December 2023
Accepted: 18 July 2024
First Online: 29 August 2024
Competing interests
: This research received financial support from the Iten-Kohaut Stiftung Foundation and the University Hospital of Zurich (USZF27070) (F.D.), as well as from the Young Talents in Clinical Research program of the SAMS and Gottfried and Julia Bangerter–Rhyner Foundation (YTCR 01/22) (F.D.). F.D. receives or has received honoraria and travel support from Merck Sharp & Dohme, Bristol–Myers Squibb, Pierre Fabre and Sun Pharma outside the submitted work. K.S.G. receives research funding from Kyowa Kirin and Almirall. O.M. has a consulting advisory role for Bristol–Myers Squibb and Pierre Fabre, receives research funding from Bristol–Myers Squibb, Roche, Pierre Fabre, Amgen and MSD along with travel and accommodation expenses from Bristol–Myers Squibb. R.G. reports honoraria from Bristol–Myers Squibb, Merck Sharp & Dohme, Roche/Genentech, Novartis, Merck Serono, Almirall Hermal, Amgen, Sun Pharma, Pierre Fabre, Sanofi/Regeneron and Immunocore; a consulting or advisory role for Bristol–Myers Squibb, Merck Sharp & Dohme, Roche/Genentech, Novartis, Almirall Hermal, 4SC, Amgen, Pierre Fabre, Merck Serono, Sun Pharma, Sanofi, and Immunocore; research funding from Novartis, Amgen, Merck Serono, Sun Pharma, Sanofi, Almirall Hermal and Kyowa Kirin; and travel and accommodations expenses from Pierre Fabre, Sun Pharma and Boehringer Ingelheim. C.M.M. has received research grants to the institution from Eli Lilly, AstraZeneca, Roche, Amgen, Novartis, Novo Nordisk and MSD, including speaker or consultant fees. G.V.L. is consultant advisor for Agenus, Amgen, Array Biopharma, AstraZeneca, Boehringer Ingelheim, Bristol–Myers Squibb, Evaxion, Hexal AG (Sandoz Company), Highlight Therapeutics, Innovent Biologics USA, Merck Sharpe & Dohme, Novartis, OncoSec, PHMR, Pierre Fabre, Provectus, Qbiotics and Regeneron. M.P.L. has received project-specific research funding from Roche, Novartis, Molecular Partners and Oncobit. R.D. has intermittent, project-focused consulting and/or advisory relationships with Novartis, Merck Sharp & Dhome, Bristol–Myers Squibb, Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym, Second Genome, Regeneron, Alligator, T3 Pharma, MaxiVAX SA, Pfizer and touchIME, all of which took place outside the submitted work. All other authors declare no competing interests.
